Skip to main content

RBC Capital Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)

Tipranks - Tipranks - Thu May 15, 2025

In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.92.

Confident Investing Starts Here:

Renza covers the Healthcare sector, focusing on stocks such as Cormedix, Jazz Pharmaceuticals, and Pacira Pharmaceuticals. According to TipRanks, Renza has an average return of 7.7% and a 40.29% success rate on recommended stocks.

Inovio Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $6.67, implying a 247.40% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Hold rating on the stock with a $3.00 price target.

See today’s best-performing stocks on TipRanks >>

INO market cap is currently $71.15M and has a P/E ratio of -0.48.

Read More on INO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).